Commentary

Parti
Choosing whether to use a TCA or SSRI as first-line treatment of depression remains a controversial problem despite many trials and meta-anaiyses. This detailed systematic review by the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) examines the issue in more depth than most of its predecessors and reaches conclusions that agree with much (but not all) previous work. What is new is the exploration of dosage of TCAs and side effects.
There has long been a consensus that TCAs are only effective in doses > 100 nig of amitriptyline or equivalent (I). Despite this consensus, considerable evidence exists that gen-
Data extraction
Data were extracted on efficacy, study completion, and adverse events.
Main results
162 randomised conn-oiled trials were reviewed. SSRIs and TCAs were equally effective, and the study completion rates did not differ. SSRIs increased the occurrence of 7 adverse events and decreased the occurrence of 3 adverse events compared with TCAs (Table) . Incidence of palpitations, urinary disturbance, fatigue, tremor, hypotension, {blurred vision, anorexia, and sweating}* did not differ. era! practitioners treat depression with lowdose TCAs. One strong argument in favour of SSRIs is the relative ease with which dierapeucic doses may be attained. However, this review shows that even when standard SSRI doses are compared with low-dose TCAs, efficacy does not differ. This finding is less surprising dian it may seem: The evidence that high doses of TCAs are required is flimsy and based on a handful of small trials. SSRIs are pharmacologically "cleaner" and, therefore, we are often told, have fewer side effects. This systematic review is the first to assess the frequency of side effects and shows that patients on SSRIs report nausea and anxiety, whereas those on TCAs complain of constipation and dry mouth. SSRIs were associated wit! greater total number of side effects tlj TCAs,-a finding that may have many) terpretations but runs counter to promotional literature. Which drug is t er tolerated? This question is usually:? swered by using the proxy measuredropout rates from trials, and this re? found similar dropout rates for both.laments, except in adult outpatients ?! were more likely to drop out on Part II Whereas previous meta-anaiyses geneagreed with the conclusions of the firstp* of the report by CCOHTA, theirf nomic modelling will be more content 
Conclusion
